BridgeBio Pharma Inc BBP-418 Update Transcript
Good day, and thank you for standing by. Welcome to today's discussion with BridgeBio, which will cover the company's novel bioassay, updates on Phase II data and the Phase III trial design for BBP-418 in Limb-girdle Muscular Dystrophy Type 2i, known as LGMD2i.
(Operator Instructions) Please be advised that today's conference is being recorded. I would now like to introduce your speakers for today, Dr. Jeffrey Rosenfeld, MD, PhD, a specialist in neuromuscular medicine and Professor of Neurology at Loma Linda University School of Medicine; Dr. Douglas Sproule, CMO of Bridge Bio's LGMD2i program; and Christine Siu, CEO of BridgeBio's LGMD2i program.
I will now hand it over to Neil Kumar, CEO.
All right. Thank you, operator, and thanks, everyone, for taking the time to join us this morning. As a brief reminder, and as noted on Slide 2, we will be making forward-looking statements today. Please refer to our filings with the SEC for further information.
All
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |